Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 11/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22571446 | 1.00 | RXFP1 (0.44) | RXFP1ABCG2KMT2AMAPK8HDAC3 | |
| SCHEMBL30463789 | 0.91 | RXFP1 (0.46) | RXFP1ABCG2KMT2AMAPK8HDAC3 | |
| SCHEMBL22571429 | 0.91 | RXFP1 (0.46) | RXFP1ABCG2KMT2AMAPK8HDAC3 | |
| SCHEMBL22556345 | 0.89 | RXFP1 (0.43) | RXFP1ABCG2MAPK8PPARGPPARD | |
| SCHEMBL23701547 | 0.88 | RXFP1 (0.45) | RXFP1ABCG2KMT2AMAPK8PPARG | |
| SCHEMBL22571364 | 0.87 | RXFP1 (0.42) | RXFP1ABCG2MAPK8PPARGPPARD | |
| SCHEMBL30463742 | 0.87 | RXFP1 (0.42) | RXFP1ABCG2MAPK8PPARGPPARD | |
| SCHEMBL22556350 | 0.86 | TRPV4 (0.43) | RXFP1ABCG2MAPK8HDAC3HDAC1 | |
| SCHEMBL23389071 | 0.86 | POLB (0.43) | KMT2ANPSR1 | |
| SCHEMBL22556510 | 0.83 | RXFP1 (0.45) | RXFP1ABCG2MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661403-B2 | Oxadiazole compounds | YAP1, TEAD2, TEAD3 | RXFP1 3511/4885ABCG2 2985/4885KMT2A 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.